Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.40 |
| ▸ | GSR | P00390 | 2/20 | 0.40 |
| ▸ | BHMT | Q93088 | 3/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25660444 | 1.00 | SLC7A5 (0.43) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL12189727 | 0.82 | SLC1A2 (0.43) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL18762462 | 0.82 | SLC1A2 (0.43) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL7376089 | 0.82 | SLC1A2 (0.43) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL15344586 | 0.80 | SLC7A5 (0.41) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL18762498 | 0.80 | SLC7A5 (0.41) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL1979860 | 0.80 | SLC7A5 (0.41) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL31207001 | 0.80 | SLC7A5 (0.41) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL21664443 | 0.80 | SLC7A5 (0.52) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 | |
| SCHEMBL11971354 | 0.80 | SLC7A5 (0.41) | SLC7A5GRIK1PTGS1SLC7A11SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521595-B1 | Treating alopecia; maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair | LG CHEMICAL, LTD. (KR) | 2003-02-18 | — | — | US | claimed |
| WO-2024158815-A1 | USE OF WS635 TO TREAT ALZHEIMER'S DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-114230498-A | Preparation method of beta- (dimethylamino) ethyl p-toluenesulfonic acid mercapto ester hydrochloride | 湖北华世通生物医药科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-105169369-B | Treat and prevent the method and pharmaceutical composition of hepatitis C infection | 中美华世通生物医药科技（武汉）有限公司 | 2019-10-18 | — | — | CN | disclosed |
| CN-108273065-A | A kind of ophthalmic composition | 药品配送方案有限公司 | 2018-07-13 | — | — | CN | disclosed |
| CN-105169369-A | Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection | SCYNEXIS INC | 2015-12-23 | — | — | CN | disclosed |
| CN-101316606-B | Methods and pharmaceutical compositions for treating and preventing hepatitis C infection | SCYNEXIS INC | 2015-05-27 | — | — | CN | disclosed |
| CN-101773661-B | 3-ether and 3-thioether substituted cyclosporin derivatives for treatment and prevention of hepatitis c infection | SCYNEXIS INC | 2013-09-25 | — | — | CN | disclosed |
| CN-101068829-B | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c virus infection | SCYNEXIS INC | 2012-05-30 | — | — | CN | disclosed |
| US-20090298751-A1 | Arylalkyl and Heteroarylalkyl Derivaties of Cyclosporine a for the Treatment and Prevention of Viral Infection | SCYNEXIS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| CN-101316606-A | Methods and pharmaceutical compositions for treating and preventing hepatitis C infection | SCYNEXIS INC (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-101316859-A | Arylalkyl and heteroarylalkyl derivatives of cyclosporin A for the treatment and prevention of viral infections | SCYNEXIS INC (US) | 2008-12-03 | — | — | CN | disclosed |
| EP-1802650-A4 | 3-ETHER AND 3-THIOETHER SUBSTITUTED CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | SCYNEXIS INC (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1931696-A1 | ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION | Scynexis, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| CN-101068829-A | 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c virus infection | SCYNEXIS INC (US) | 2007-11-07 | — | — | CN | disclosed |
| EP-1802650-A2 | 3-ETHER AND 3-THIOETHER SUBSTITUTED CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | Scynexis, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007041631-A1 | ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION | SCYNEXIS, INC. (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2006039668-A2 | 3-ETHER AND 3-THIOETHER SUBSTITUTED CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION | SCYNEXIS, INC (US) | 2006-04-13 | — | — | WO | disclosed |
| US-6521595-B1 | Treating alopecia; maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair | LG CHEMICAL, LTD. (KR) | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | SLC7A5 75/4885GRIK1 2914/4885PTGS1 4864/4885 |
| US-20090298751-A1 | Arylalkyl and Heteroarylalkyl Derivaties of Cyclosporine a for the Treatment and Prevention of Viral Infection | HAVCR2, CYP2B6, CYP1B1 | SLC7A5 904/4885GRIK1 4857/4885PTGS1 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.